EXACT Sciences Corporation

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Company Growth (employees)
Type
Public
HQ
Madison, US
Founded
1995
Size (employees)
736 (est)
EXACT Sciences Corporation was founded in 1995 and is headquartered in Madison, US

EXACT Sciences Corporation Office Locations

EXACT Sciences Corporation has an office in Madison
Madison, US (HQ)
441 Charmany Dr

EXACT Sciences Corporation Data and Metrics

EXACT Sciences Corporation Financial Metrics

EXACT Sciences Corporation's revenue was reported to be $99.4 m in FY, 2016
USD

Net income (Q1, 2017)

(34.9 m)

EBIT (Q1, 2017)

(35.5 m)

Market capitalization (17-Aug-2017)

4.2 b

Cash (31-Mar-2017)

39.2 m
EXACT Sciences Corporation's current market capitalization is $4.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.1 m1.8 m39.4 m99.4 m

Revenue growth, %

(57%)2093%152%

Cost of goods sold

4.3 m24.5 m45.2 m

Gross profit

(2.5 m)14.9 m54.2 m

Gross profit Margin, %

(141%)38%55%

Sales and marketing expense

112.8 m

R&D expense

33.5 m

General and administrative expense

76.9 m

Operating expense total

50.9 m98 m174 m223.2 m

EBIT

(46.8 m)(100.5 m)(159.1 m)(169 m)

EBIT margin, %

(1128%)(5592%)(403%)(170%)

Interest expense

69 k51 k6 k213 k

Net Income

(46.5 m)(100 m)(157.8 m)(167.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.3 m8.1 m12.6 m

Cost of goods sold

924 k4.2 m5.1 m7.5 m9.1 m10.1 m12.2 m17 m

Gross profit

54 k3 m5.1 m

Gross profit Margin, %

1%37%40%

Sales and marketing expense

6.2 m13.2 m16.5 m20.6 m23.1 m25.7 m30.3 m26.3 m38.8 m

R&D expense

7.2 m9.1 m6.6 m8.1 m9.9 m10.1 m8.6 m7.6 m8 m

General and administrative expense

6.2 m9 m13 m13.7 m15.4 m17.8 m17.3 m20.3 m20.1 m

Operating expense total

19.6 m31.3 m36.1 m42.4 m48.4 m53.7 m56.2 m54.2 m66.9 m

EBIT

(19.6 m)(32.2 m)(36 m)(39.4 m)(43.3 m)(47.9 m)(45.1 m)(38.3 m)(35.5 m)

EBIT margin, %

(844%)(485%)(343%)

Interest expense

(13 k)(12 k)(11 k)(54 k)(50 k)

Interest income

107 k(40 k)(53 k)(54 k)

Net Income

(35.5 m)(67.6 m)(35.8 m)(74.9 m)(117.8 m)(47.5 m)(44.8 m)(37.8 m)(34.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.9 m58.1 m41.1 m48.9 m

Accounts Receivable

1.4 m8.5 m

Inventories

2.2 m3.5 m7.6 m6.8 m

Current Assets

135.5 m291.7 m326.1 m333.6 m

PP&E

11.2 m

Total Assets

146.6 m311.6 m364.3 m377 m

Accounts Payable

761 k2.6 m3.3 m710 k

Total Debt

4.6 m

Current Liabilities

7.8 m17.5 m26.7 m30.7 m

Total Liabilities

41.7 m

Additional Paid-in Capital

455.2 m709 m904.9 m1.1 b

Retained Earnings

(320.8 m)(420.8 m)(578.6 m)(745.8 m)

Total Equity

135.3 m289 m326.9 m335.3 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

20.7 m27.8 m40.7 m33.8 m31.5 m52.2 m49 m63.4 m39.2 m

Accounts Receivable

1.6 m2.2 m4.2 m5.6 m7.4 m7.9 m16.2 m

Inventories

2.7 m5.4 m6.3 m6 m8.2 m8.4 m7.7 m7.9 m

Current Assets

238.8 m216.2 m256 m223.3 m359.4 m284.1 m247.2 m359 m306.2 m

PP&E

17 m18.4 m

Total Assets

255.8 m234.7 m278.8 m253 m394 m323.8 m288.5 m403.2 m350.3 m

Accounts Payable

357 k4.6 m2 m1.3 m1.5 m2.8 m3.1 m2.3 m891 k

Current Liabilities

9.8 m16.8 m14.5 m18.7 m23.5 m24.7 m28.4 m30.1 m29.9 m

Additional Paid-in Capital

598.3 m602.6 m713.9 m719.6 m898.8 m913.5 m919.3 m1.1 b1.1 b

Retained Earnings

(356.3 m)(388.4 m)(456.6 m)(495.7 m)(538.6 m)(626.1 m)(670.8 m)(708.7 m)(781.2 m)

Total Equity

242.9 m215.1 m258.2 m224.8 m361.3 m288.3 m249.4 m362.3 m309.5 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.5 m)(100 m)(157.8 m)(167.2 m)

Accounts Receivable

(1.4 m)(3.6 m)8.5 m

Inventories

(1.6 m)(1.3 m)(3.1 m)7.1 m

Accounts Payable

(2.9 m)1.9 m661 k710 k

Cash From Operating Activities

(39.3 m)(80.9 m)(134 m)

Purchases of PP&E

(9.3 m)(12.5 m)(20.1 m)

Cash From Investing Activities

(35.5 m)(117.8 m)(64.8 m)

Cash From Financing Activities

74.3 m244 m181.8 m

Interest Paid

95 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(35.5 m)(67.6 m)(35.8 m)(74.9 m)(117.8 m)(47.5 m)(44.8 m)(37.8 m)(34.9 m)

Depreciation and Amortization

2.3 m

Accounts Receivable

(205 k)(775 k)(2.8 m)(688 k)7.4 m7.9 m16.2 m

Inventories

(2.7 m)

Accounts Payable

(404 k)3.9 m(646 k)(1.3 m)(1.1 m)(467 k)3.1 m2.3 m891 k

Cash From Operating Activities

(28.9 m)(50 m)(34.5 m)(65.7 m)(100.2 m)(42.3 m)

Purchases of PP&E

(7.2 m)(9.5 m)(3.2 m)(10.7 m)(17.5 m)(2.4 m)

Cash From Investing Activities

(101.3 m)(73.2 m)16.8 m36.3 m(105.7 m)53.2 m

Cash From Financing Activities

138 m138.2 m295 k5.1 m179.3 m247 k

Interest Paid

53 k
Y, 2017

Financial Leverage

1.1 x

EXACT Sciences Corporation Operating Metrics

FY, 2015

Patents Pending

57

Patents Issued

77

EXACT Sciences Corporation Market Value History

Traffic Overview of EXACT Sciences Corporation

EXACT Sciences Corporation Online and Social Media Presence

EXACT Sciences Corporation Company Life and Culture

You may also be interested in